The Standard Glass Lining Technology Limited IPO offers investors an opportunity to invest in a leading engineering equipment manufacturer specializing in pharmaceutical and chemical sectors. Here’s a detailed breakdown:
IPO Details
- IPO Type: Book Built Issue
- Issue Size: ₹410.05 Cr
- Fresh Issue: ₹210.00 Cr (1.5 Cr shares)
- Offer for Sale: ₹200.05 Cr (1.43 Cr shares)
- Price Band: ₹133 – ₹140 per share
- Lot Size: 107 shares
- Listing: NSE, BSE
- Face Value: ₹10 per share
Important Dates
- IPO Open Date: January 6, 2025
- IPO Close Date: January 8, 2025
- Allotment Date: January 9, 2025
- Refunds Initiated: January 10, 2025
- Shares Credited to Demat: January 10, 2025
- Listing Date: January 13, 2025
Minimum Investment
- Retail: ₹14,980 (1 lot = 107 shares)
- sNII: ₹2,09,720 (14 lots = 1,498 shares)
- bNII: ₹10,03,660 (67 lots = 7,169 shares)
Standard Glass Lining Technology Limited IPO GMP
| Date | IPO GMP | Subject to |
|---|---|---|
| 8 January | ₹95 | ₹7,000 |
| 7 January | ₹95 | ₹7,000 |
| 6 January | ₹95 | ₹7,000 |
| 4 January | ₹90 | ₹7,000 |
| 3 January | ₹90 | ₹7,000 |
| 2 January | ₹83 | ₹7,000 |
Financial Performance
Restated Consolidated Financials
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Revenue (₹ Cr) | 312.1 | 549.68 | 500.08 | 241.5 |
| Profit After Tax (₹ Cr) | 36.27 | 60.01 | 53.42 | 25.15 |
| Assets (₹ Cr) | 756.52 | 665.38 | 347.79 | 298.11 |
| Net Worth (₹ Cr) | 447.8 | 409.92 | 156.67 | 69.91 |
Key Metrics
- Market Cap: ₹2792.88 Cr
- ROE: 20.74%
- ROCE: 25.49%
- Debt-to-Equity: 0.32
- EPS (Post-IPO): ₹3.64
- P/E Ratio (Post-IPO): 38.5x
Objects of the Issue
- Capital Expenditure: Purchase of machinery and equipment.
- Debt Repayment: Partial/full repayment of borrowings.
- Inorganic Growth: Strategic investments/acquisitions.
- Subsidiary Investment: Funding capital expenditure of S2 Engineering Industry Private Limited.
- General Corporate Purposes.
Competitive Strengths
- Specialization in glass-lined equipment for pharmaceutical and chemical sectors.
- In-house production capabilities.
- Long-term relationships with top pharmaceutical clients.
- Consistent financial growth and profitability.
Lead Managers
- IIFL Securities Ltd.
- Motilal Oswal Investment Advisors Limited.
Registrar
- Kfin Technologies Limited.
Should You Subscribe?
The IPO is recommended for medium to long-term investors due to the company’s:
- Steady growth in revenue and profits.
- Strong clientele in the pharmaceutical and chemical industries.
- Strategic investment plans and partial debt reduction, which may boost future profitability.
FAQs
How to apply for the IPO?
Investors can apply via ASBA or UPI through brokers like Zerodha, Angel One, etc.
What is the minimum investment?
₹14,980 for retail investors (107 shares).
When will the shares be listed?
Tentatively on January 13, 2025.
How to check IPO allotment?
Visit the registrar’s website KFin Technologies.
Is this IPO worth subscribing to?
Yes, considering the company’s consistent financial growth and strategic expansion plans.
Information Source – SEBI IPO Section